Johnson & JohnsonvsOmada Health

JNJ and OMDA stock compared: price, dividend, valuation and results, from SEC filings.

Johnson & Johnson (JNJ) has a market value of $672B and Omada Health (OMDA) $873M. Over the last year, with dividends, JNJ moved +45.4% and OMDA -29.8%. The P/E is 41.7 for JNJ and 62.2 for OMDA. Dividend yield: JNJ 1.89%, OMDA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$672B

    OMDA$873M

    JNJ is 769 times OMDA

  • Revenue, 12 months

    JNJ$99.3B

    OMDA$333M

    JNJ is 298 times OMDA

  • Net income, 12 months

    JNJ$16.1B

    OMDA$14M

    JNJ is 1,147 times OMDA

  • Operating margin

    JNJ–

    OMDA2.1%

  • ROIC

    JNJ12.4%

    OMDA2.3%

    10.1 points apart

  • P/E

    JNJ41.7

    OMDA62.2

    OMDA is 1.5 times JNJ

  • Dividend yield

    JNJ1.9%

    OMDA0.0%

    1.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+45.4%

OMDA-29.8%

100150DecFebAprJunAugOct
Returns by period
PeriodJNJWith dividendsOMDAWith dividends
1 year since November 14, 2025+45.4%Price +42.2%-29.8%Price -29.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonOMDAOmada Health

Valuation

JNJOMDA
Valuation
Price$278.70$14.08
Market value$672B$873M
Enterprise value (EV)$699B$630M
P/E41.762.2
P/E, 5-year median21.9–
P/B8.23.2
EV/EBIT39.491.8
Free cash flow yield3.1%3.2%

Results and growth

JNJOMDA
Results and growth
Revenue, 12 months$99.3B$333M
Net income, 12 months$16.1B$14M
Free cash flow, 12 months$20.6B$28M
Earnings per share, 12 months$6.59$0.23
Revenue growth, year on year6.1%53.2%
Revenue growth a year, past+2.7%over 5 years+45.6%over 2 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJOMDA
Margins and returns on capital
Gross margin67.6%70.7%
Operating margin–2.1%
Net margin16.2%4.2%
ROIC12.4%2.3%
ROE19.7%5.8%

Balance sheet

JNJOMDA
Balance sheet
Cash$17.2B$243M
Total debt$44.7B$0
Net debt / EBITDA1.1-19.7
Interest cover18.0×22.4×

Dividends and buybacks

JNJOMDA
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or OMDA

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Omada Health?

By market value, Johnson & Johnson ($672B) is about 768.9 times Omada Health ($873M), at today's prices.

How did JNJ and OMDA stock do over the last 1 years?

Since November 14, 2025, JNJ's price moved +42.2% and OMDA's -29.8%. With dividends: JNJ +45.4% (+45.4% a year), OMDA -29.8% (-29.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or OMDA?

The dividend yield at today's price is 1.89% for Johnson & Johnson and none for Omada Health. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and OMDA?

At today's price, the P/E is 41.7 for JNJ and 62.2 for OMDA. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Johnson & Johnson or Omada Health?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 4.2% for Omada Health, and the operating margin – and 2.1%. Revenue was $99.3B and $333M.

Which is the better investment, Johnson & Johnson or Omada Health?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.